




Tapinarof

Revised: February 15, 2024.

CASRN: 79338-84-4



Drug Levels and Effects

Summary of Use during Lactation

Tapinarof has not been studied during breastfeeding. Because it is poorly absorbed after topical application, it is considered a low risk to the nursing infant.[1] Do not apply tapinarof directly to the nipple and areola and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin

References

1. Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024. PubMed PMID: 38280680.

Substance Identification

Substance Name

Tapinarof

CAS Registry Number

79338-84-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Dermatological Agents